Companies Join Forces to Address Urgently Needed Quality Control of CRISPR Genome-editing

SAN DIEGO (PRWEB) January 21, 2020

COBO Technologies and Cardea Bio partner to bring solutions to challenges with the precision of Genome editing. The partners have agreed to co-develop and market a portfolio of CRISPR QC products and services for quality control (QC) of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term, the parties aim to develop a COBO branded QC device based on Cardea’s CRISPR-Chip™ QC technology for use before and after genome-editing in the pre-clinical setting.

With the new strategic partnership, the Danish company COBO Technologies, which specializes in quality control of CRISPR-modified cells of any kind, will collaborate with San Diego-based (bio)technology infrastructure company Cardea to bring powerful QC products and services for better genome-editing applications to the global life science and agriculture markets.

The partners have begun product development of a CRISPR QC tool based on Cardea’s innovative biology-gated transistors™. By adding CRISPR-Chip QC capabilities to the Cardean transistor infrastructure, the teams will be able to achieve sensitive and fast quality control of CRISPR experiment subparts (e.g. gRNAs, Cas systems and versions, on-and-off target activity) -and the resulting genome modified cells.

“There is a rapidly increasing need for better quality control of genome-edited cells. With this new QC tool based on CRISPR-Chip, researchers can easily confirm the precision of their CRISPR experiments, for example, detection of potential off-target events,” says Jens-Ole Bock, CEO and founder of COBO Technologies.

COBO’s tools include the proprietary CRISPR InDel Profiling Platform (CIPP™) developed for in-depth detection of genome editing outcomes and PIPPR® created for extensive proteome expression profiling after CRISPR edits. Beginning in 2020, the strong sales team at Nanosens (a wholly-owned Cardea subsidiary) will market and sell COBO’s services and products for quality control in the US.

“This is a unique opportunity for us to enter the global markets together with a very competent partner that is already a part of the global CRISPR QC conversation,” says Mr. Bock.

COBO and Cardea began the development of a QC CRISPR-Chip at the start of 2020.

“Cardea and its Innovation Partners are consistently finding new ways to leverage our graphene-based, biology-gated transistor infrastructure to help the world Conduct Biology™,” says Michael Heltzen, CEO of Cardea. “In this example, our proprietary, award-winning CRISPR-Chip technology provides our partner with a unique and transformational solution to gain near-instant insight into what CRISPR is doing and whether the experiment is going according to plan. If researchers around the world are going to alter the genomes of living things, we think they must get it right, hence why we are pushing hard to give them fast and precise quality control tools together with the expert team from COBO.”

“The QC CRISPR-Chip will expand and strengthen the way we do quality control of CRISPR cells today. On top of that, the platform is portable and easy to adapt to clinical settings in the future. We already have a solid customer base eager to test Cardea’s CRISPR-Chip platform, so we’re quite excited about building our product on the Cardea infrastructure,” says Mr. Bock.

The strategic partnership will be announced at the Precision Medicine World Conference in Silicon Valley, Jan. 21-24, 2020. Visit both partners at Booth #B1714 and join the panel discussion: “How CRISPR Revolutionizes Genomic Medicine” on Friday 24th at 3:30 PM, where Mr. Bock and Cardea’s CSO, Dr. Kiana Aran, will be speaking about the importance of quality control when using CRISPR.

PIPPR® and CIPP™ are trademarks of COBO Technologies. Biology-gated transistors™ and CRISPR-Chip™ is a trademark of Cardea Bio.

About Cardea

Cardea Bio is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors (“Cardean transistors”). Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical molecular signal analysis. Until now, life science data was comprised of static snapshot datasets. With Cardean transistors, the company and its Innovation Partners can generate streaming multi-omics data to measure real-time biological signals. Cardea is now manufacturing chips at scale and partners have started to significantly expand the amount, type and quality of biological data they capture by building products that Conduct Biology™. Cardea is headquartered in San Diego, California.

About COBO Technologies

COBO Technologies is a fast-growing CRO specialized in services and products for quality control of genome editing applications in research and pre-clinical fields. The company supports customers globally with detailed DNA mutation analysis and complexed protein expression profiling of cells, plants or animals modified with genome editing tools such as CRISPR-Cas9, ZFNs, Meganucleases and TALENs.

Read the full story at

Modality Solutions Announces 2019 Year-End Milestones Including ISO 9001:2015, Inc. 5000, Entrepreneur 360™ and More

HOUSTON (PRWEB) January 21, 2020

Modality Solutions specializes in integrating cold chain operations, developing transport validation strategies, supporting global regulatory applications, and executing global clinical trial operations. Milestone highlights include recognition by both Inc. 5000 and the Houston Business Journal as a fastest growing company, and ISO 9001:2015 certification with the scope of the accreditation covering consulting, design and engineering services and testing for supply chain logistics related to transport-sensitive drug products.

Modality Solutions also received the distinction of being one of the “Best Entrepreneurial Companies in America” by Entrepreneur magazine on its 2019 Entrepreneur 360™ List. “Our annual evaluation is a 360-degree analysis of top privately-held companies representing and serving a variety of industries,” explains Lisa Murray, Chief Insights Officer of Entrepreneur Media, Inc. “These businesses are real-world case studies for any entrepreneur who seeks to master the four pillars that can greatly impact the longevity and growth of their businesses. With the Entrepreneur 360, success is measured by achieving balance throughout the entire organization, predicated by revenue.”

Co-founder and President, Gary Hutchinson, was accepted into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and technology executives. Hutchinson was vetted and selected by a review committee based on the depth and diversity of his experience. Criteria for acceptance include a track record of successfully impacting business growth metrics, as well as personal and professional achievements and honors.

Modality Solutions achieved its first-ever ranking on Inc. Magazine’s annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. It reported a three-year revenue growth of 120 percent and ranked No. 47 in the Inc. industry category of top engineering companies. Also, in its first appearance on the Houston Business Journal’s Fast 100 list, the company ranked No. 91 with reported two-year revenue growth of 56 percent.

“2019 was a stellar year for us, with ISO 9001:2015 certification, recognition by Inc. and Entrepreneur magazines, participation in the Forbes Tech Council, and continuing to partner with our clients to validate safe and effective cold chains,” said President Hutchinson. “As we continue our mission into the next decade, our vision for the future is to continue to expand with our team of experienced engineers our ongoing role to promote safe, effective, and validated cold chain for a whole range of therapies.”

The company’s commitment to growth included promoting from within Andrew Larrigan and Robert Battista to Senior Consulting Engineers and adding Rachel Sawyer as Consulting Engineer. In her new position, Sawyer works with other dedicated project engineers to ensure proper design and use of cold chain systems.

The biopharmaceutical industry benefited from Modality Solutions’ first live webinar on Sept. 19. Principals Gary Hutchinson and Daniel Littlefield covered a step-by-step cold chain validation process to help pharmaceutical companies meet and exceed increasingly stringent regulatory expectations, including monoclonal antibodies, antibody-drug conjugates, and cell therapies. To access the on-demand replay of “Cold Chain Validation Best Practices Including Immunotherapy” go to

To wrap up its year of achievements, Modality Solutions was a Silver Sponsor and cold chain validation workshop presenter at the Biomanufacturing World Summit (BMWS19) Conference, November 11-12, 2019, at the Hilton La Jolla Torrey Pines in San Diego, California. Hutchinson and Littlefield presented “Cold Chain Validation Best Practices Including Immunotherapy.”

To learn more about Modality Solutions, visit

About Modality Solutions, LLC

Founded in 2011, Modality Solutions, a leading biopharmaceutical cold chain engineering firm, specializes in integrating cold chain operations, developing transport validation strategies, supporting global regulatory applications, and executing global clinical trial operations. By combining the best practices of process validation, systems qualification, and risk assessment, Modality Solutions has earned the reputation of ensuring regulatory compliance, product quality, and patient safety. As an ISO 9001:2015 certified, Inc. 5000, Houston Business Journal Fast 100, Entrepreneur 360™, and Forbes Technology Council company, Modality Solutions’ team of engineers are experts at delivering cold chain thermal packaging design and qualification, conducting transport simulation testing with its Advantage Transport Simulation Laboratory™, and designing controlled-environment logistics solutions. For more information, visit

Read the full story at

Microbial Discovery Group Appoints New Southern Midwest Industrial and Institutional Account Manager

FRANKLIN, Wis. (PRWEB) January 21, 2020

Microbial Discovery Group LLC (MDG) is pleased to announce the hiring of Darrell Taylor as Southern Midwest Region Industrial and Institutional (I&I) Account Manager. Darrell will focus on servicing MDG’s partners with strategic attention to the SporActiv™ product line.

Darrell brings over 30 years of sales experience working across multiple different market sectors such as; transportation, office products, and consumer electronics.

“From my first interactions with everyone, I knew there was something special happening here. Everyone I met made me feel at home. MDG is clearly driven by the desire to get the job done but the company also recognizes people are their greatest resource. To be a part of this environment is exciting!” stated Darrell.

“We are thrilled to have Darrell join our growing team. Over the past year, the I&I market has been a focus of MDG; having an experienced account manager, like Darrell, dedicated to this market will allow us to bring our partners sought-after solutions and support. We’re looking forward to the trusted relationships Darrell will build within this market,” added Jenna Trusso, Product Manager.

About Microbial Discovery Group

Microbial Discovery Group (MDG) is an R&D driven product development and Bacillus fermentation company. MDG has the capabilities to ensure success. When partnering with MDG, you can expect high quality, consistent Bacillus strain manufacturing delivered with efficiency and integrity. MDG is passionate about applying scientific principles to create indispensable solutions for our partners while working to Feed, Clean, and Save the World. For more information on Microbial Discovery Group, visit

Read the full story at